MARKET

ACHV

ACHV

Achieve Life Sciences Inc
NASDAQ
5.39
+0.03
+0.56%
Opening 15:03 05/29 EDT
OPEN
5.32
PREV CLOSE
5.36
HIGH
5.59
LOW
5.31
VOLUME
133.99K
TURNOVER
0
52 WEEK HIGH
8.37
52 WEEK LOW
3.030
MARKET CAP
185.10M
P/E (TTM)
-4.1890
1D
5D
1M
3M
1Y
5Y
Achieve Life Sciences (ACHV) Receives a Buy from Lake Street
TipRanks · 16h ago
ACHIEVE LIFE SCIENCES INC: TARGETING FIRST HALF OF 2025 FOR NDA SUBMISSION IN UNITED STATES
Reuters · 17h ago
ACHIEVE LIFE SCIENCES ANNOUNCES INITIATION OF ORCA-OL CLINICAL TRIAL EVALUATING LONG-TERM EXPOSURE OF CYTISINICLINE IN PEOPLE WHO SMOKE OR USE NICOTINE E-CIGARETTES
Reuters · 17h ago
Weekly Report: what happened at ACHV last week (0520-0524)?
Weekly Report · 2d ago
Weekly Report: what happened at ACHV last week (0513-0517)?
Weekly Report · 05/20 09:34
Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting
Data from the Phase 2 ORCA-V1 vaping cessation trial will be presented today, May 17, 2024, at the Society of General Internal Medicine Annual Meeting in Boston. Achieve Life Sciences, Inc. Is committed to the development of cytisinicline for smoking cessation and nicotine dependence.
Barchart · 05/17 07:00
Buy Rating Affirmed: Achieve Life Sciences’ Promising Path to Cytisinicline NDA and Strong Financial Outlook
TipRanks · 05/14 14:45
Buy Rating Affirmed for Achieve Life Sciences Amid Positive Drug Development Progress and Strong Financial Position
TipRanks · 05/13 12:45
More
About ACHV
Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over the counter (OTC) products.

Webull offers Achieve Life Sciences Inc stock information, including NASDAQ: ACHV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACHV stock methods without spending real money on the virtual paper trading platform.